Sandbox G
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Guillermo Rodriguez Nava, M.D. [2]
Overview
- If a patient has a strong pre-test probability for CDI, empiric therapy should be considered regardless of the laboratory testing result[1].
- Any antimicrobial agent should be discontinued</ref> [1].
- Current guidelines recommend to choose the treatment regimen based on the severity of the disease[2] [1][3][4]:
- Mild: diarrhea as only symptom.
- Moderate: raised WCC but <15,000 cells/mL and serum creatine <1.5 times baseline.
- Severe: leucocytosis >15,000 cells/mL OR serum creatinene level >1.5 times baseline or abdominal tenderness and serum albumin < 3 g/dL.
- Severe complicated: hypotension or shock, ileus, megacolon, leucocytosis >20,000 cells/mL or leucopenia <2,000, lactate >2.2 mmol/L, delirium, fever >organ failure,; ≥ 38.5 °C.
- Duration: recommendations stablish a 10-14 days treatment. If clinical response in 5-7 days, complete 10[4].
- Do not use metronidazole beyond the first recurrence episode of CDI or for long-term therapy because of the risk of neurotoxicity[2].
- For mild-to-moderate patients who are intolerant/allergic to metronidazole and for pregnant/breastfeeding women, vancomycin should be used at standard dosing[1].
- The use of anti-peristaltic agents to control diarrhea from confirmed or suspected CDI should be limited or avoided</ref> [1].
- Supportive care should be delivered to all patients with severe or severe complicated CDI[1].
- CT scanning of the abdomen and pelvis is recommended in patients with severe complicated CDI[1].
- Surgical consult should be obtained in all patients with complicated CDI[1].
- If there is a third recurrence after a pulsed vancomycin regimen, fecal microbiota transplant should be considered[1].
Medical Therapy
▸ Click on the following categories to expand treatment regimens.[1][2][3][4][5]
Initial episode ▸ Mild to moderate ▸ Severe ▸ Severe complicated Recurrence ▸ First recurrence ▸ Second recurrence |
|
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH; et al. (2013). "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections". Am J Gastroenterol. 108 (4): 478–98, quiz 499. doi:10.1038/ajg.2013.4. PMID 23439232.
- ↑ 2.0 2.1 2.2 Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.
- ↑ 3.0 3.1 Planche, Tim (2013). "Clostridium difficile". Medicine. 41 (11): 654–657. doi:10.1016/j.mpmed.2013.08.003. ISSN 1357-3039.
- ↑ 4.0 4.1 4.2 Knight, Christopher L.; Surawicz, Christina M. (2013). "Clostridium difficile Infection". Medical Clinics of North America. 97 (4): 523–536. doi:10.1016/j.mcna.2013.02.003. ISSN 0025-7125.
- ↑ Kelly CP, LaMont JT (2008). "Clostridium difficile--more difficult than ever". N Engl J Med. 359 (18): 1932–40. doi:10.1056/NEJMra0707500. PMID 18971494.